8-K: Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024, and is progressing towards a merger agreement with Renovaro.

Summary

• Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.
• The company is working towards a definitive merger agreement with Renovaro, Inc.
• Renovaro has advanced the first tranche of financing to Predictive to initiate the integration of AI/ML platform technologies.
• Predictive Oncology completed the sale of assets related to its wholly owned subsidiary, Skyline Medical Inc., to DeRoyal Industries.
• The company has developed a registry of promising drug candidates that can potentially be repurposed for additional or alternative indications.
• Predictive Oncology partnered with Tecan Group Ltd. to expand high-throughput drug screening to include human tumor spheroids.
• The company plans to launch its ChemoFx drug response assay in Europe and expand availability in the United States.
• Predictive Oncology received more than $3.0 million in combined gross proceeds during the first three months of 2025.
• The company concluded the fourth quarter of 2024 with $734,673 in cash and cash equivalents, compared to $8.7 million as of December 31, 2023.
• Basic and diluted net loss per common share from continuing operations for the year ended December 31, 2024, decreased approximately 33% to $1.99, as compared to $2.99 for the year ended December 31, 2023.
• Revenues for the years ended December 31, 2024, and December 31, 2023, were primarily derived from its Eagan operating segment.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is pursuing a merger and has made some progress in its AI/ML initiatives, the financial results are weak, with a significant loss and a substantial decrease in cash reserves. The merger is a potential positive, but its success is not guaranteed.

Positives

• The company is progressing towards a merger agreement with Renovaro, Inc., which could create a new AI/ML drug discovery company.
• The sale of Skyline Medical Inc. assets to DeRoyal Industries is expected to reduce the company's ongoing expense run rate.
• The company has developed a registry of promising drug candidates for repurposing.
• Predictive Oncology partnered with Tecan Group Ltd. to expand high-throughput drug screening.
• The company plans to launch its ChemoFx drug response assay in Europe and expand availability in the United States.
• Basic and diluted net loss per common share from continuing operations decreased approximately 33% to $1.99.

Negatives

• Predictive Oncology reported a loss from continuing operations of approximately $10.8 million for the year ended December 31, 2024.
• Cash and cash equivalents decreased to $734,673 as of December 31, 2024, compared to $8.7 million as of December 31, 2023.
• The company had a stockholders deficit of $(202,610) compared to $8.3 million of Stockholders Equity as of December 31, 2023.

Risks

• The company's future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, the risks related to the success of our collaboration arrangements, commercialization activities and product sales levels by our collaboration partners.
• The company's cash position has significantly decreased.

Future Outlook

The company is focused on completing the merger with Renovaro and leveraging its AI/ML capabilities for drug and biomarker discovery. They anticipate the signing of a definitive merger agreement imminently following the successful completion of due diligence.

Management Comments

• Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology, stated that the company took tangible steps to sharpen its focus on its core AI/ML-based drug and biomarker discovery capabilities while implementing efficiencies across the organization to maximize long-term shareholder value.
• Vennare also noted that the pending merger with Renovaro, if completed, will create a new AI/ML drug discovery company with unique advantages in the marketplace and the potential to meaningfully improve outcomes for cancer patients.

Industry Context

The announcement reflects the ongoing trend of companies in the biotechnology sector focusing on AI/ML-driven drug discovery and personalized medicine. The merger with Renovaro suggests a strategic move to combine resources and expertise in this competitive landscape.

Comparison to Industry Standards

• Predictive Oncology's revenue of $1.6 million is relatively low compared to established pharmaceutical companies, but is not unusual for a development-stage biotechnology company.
• The company's focus on AI/ML aligns with industry trends, as companies like Recursion Pharmaceuticals and Exscientia are also leveraging AI for drug discovery.
• The planned launch of ChemoFx in Europe is similar to other companies expanding their diagnostic offerings geographically.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the decrease in cash reserves.
• Employees may be affected by the ongoing integration efforts and potential restructuring following the merger.
• Customers may benefit from the expanded availability of the ChemoFx assay and the development of new AI/ML-driven drug discovery capabilities.

Next Steps

• The companies continue to work towards the completion of due diligence and the finalization of a definitive merger agreement.
• The company plans to launch its ChemoFx drug response assay in Europe and expand availability in the United States.

Key Dates

Keywords

Predictive Oncology, Renovaro, Merger, Financial Results, AI/ML, Drug Discovery, ChemoFx, Oncology, Biorepository, CLIA Laboratory